Novo Nordisk cuts Wegovy price 50%, Ozempic 35% starting 2027. Move comes one day after CagriSema trial failed vs Lilly's Zepbound.

Novo Nordisk Slashes Wegovy and Ozempic Prices by Up to 50%—One Day After CagriSema Trial Failure

Novo Nordisk's CagriSema achieved 23% weight loss vs 25.5% for Lilly's Zepbound. Stock plunges 15% to lowest since 2021—what it means for the obesity drug war.

Novo Nordisk's CagriSema Loses to Eli Lilly's Zepbound in Head-to-Head Trial, Stock Hits 5-Year Low

CagriSema achieves 23% weight loss vs Zepbound's 25.5% in REDEFINE 4, sending Novo Nordisk shares down 15% as Eli Lilly extends dominance in obesity market.

Novo Nordisk's CagriSema Fails to Match Eli Lilly's Zepbound in Head-to-Head REDEFINE 4 Trial

Novo Nordisk sues Hims & Hers over compounded Wegovy copies. HIMS crashes 25% as FDA crackdown signals broader war on GLP-1 compounders.

Novo Nordisk Sues Hims & Hers for Patent Infringement as FDA Cracks Down on GLP-1 Compounders

Novo Nordisk forecasts 5-13% sales decline in 2026—first annual drop in a decade. Stock crashes 12% as Eli Lilly takes market share.

NOVO NORDISK A S (NVO)·Earnings Reports

Q4 2025

Analyst Coverage

Recent News about NOVO NORDISK A S

Novo Nordisk Slashes Wegovy and Ozempic Prices by Up to 50%—One Day After CagriSema Trial Failure

Novo Nordisk's CagriSema Loses to Eli Lilly's Zepbound in Head-to-Head Trial, Stock Hits 5-Year Low

Novo Nordisk's CagriSema Fails to Match Eli Lilly's Zepbound in Head-to-Head REDEFINE 4 Trial

Novo Nordisk Sues Hims & Hers for Patent Infringement as FDA Cracks Down on GLP-1 Compounders

Novo Nordisk Warns of Sales Decline in 2026—Stock Plunges 12%

Novo Nordisk Cuts Wegovy Prices 50% in China as Patent Cliff Looms